Takeda Pharmaceutical Company Limited (TAK)
After hours:
| Previous Close | 13.47 |
| Open | 13.43 |
| Bid | 13.00 x 2900 |
| Ask | 13.50 x 4000 |
| Day's Range | 13.40 - 13.56 |
| 52 Week Range | 12.77 - 16.39 |
| Volume | |
| Avg. Volume | 1,571,885 |
| Market Cap | 42.765B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 46.59 |
| EPS (TTM) | 0.29 |
| Earnings Date | Jul 31, 2024 |
| Forward Dividend & Yield | 0.64 (4.74%) |
| Ex-Dividend Date | Sept 28, 2023 |
| 1y Target Est | 18.21 |
Business WireTakeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2024--Takeda (TSE: 4502/NYSE:TAK) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall dis
BloombergBlackstone Is Considering the Sale of Alinamin Pharmaceutical, Sources Say
(Bloomberg) -- Blackstone Inc. is considering a sale of Japanese consumer health-care firm Alinamin Pharmaceutical Co., which used to be owned by Takeda Pharmaceutical Co., according to people familiar with the situation.Most Read from BloombergKey Engines of US Consumer Spending Are Losing Steam All at OnceGameStop Shares Surge as Gill’s Reddit Return Shows Huge BetMnuchin Chases Wall Street Glory With His War Chest of Foreign MoneyHomebuyers Are Starting to Revolt Over Steep Prices Across USAM
Business WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
OSAKA, Japan & CAMBRIDGE, Mass. & NEW YORK, June 01, 2024--Takeda (TSE:4502/NYSE:TAK) and Pfizer (NYSE: PFE) today announced that the German Hodgkin Study Group (GHSG) will present positive results from the Phase 3 HD21 trial evaluating ADCETRIS® (brentuximab vedotin) in combination with chemotherapy as a late-breaking oral presentation at the 60th American Society of Clinical Oncology (ASCO) Annual Meeting (LBA7000) and at the 29th European Hematology Association (EHA) Annual Meeting (S225). Th
